Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 29;142(16):1371–1386. doi: 10.1182/blood.2022018833

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 2. — Five-year cumulative estimates (Kaplan-Meier) of end-stage kidney disease–free survival. HRs and 95% CIs calculated using the Cox proportional hazard regression model, P values calculated using the log-rank test, and the NNT are shown where appropriate. (A) Treated vs control, CaHUS with mutation or FHAA. (B) Children vs adults, CaHUS with mutation or FHAA. (C) Control group based on the mutation type. (D) Treated group, based on the mutation type. (E) Treated vs control, individuals with CFH mutation subgroup. (F) Treated vs control, individuals with CD46 mutation subgroup.

Figure 2. — Five-year cumulative estimates (Kaplan-Meier) of end-stage kidney disease–free survival. HRs and 95% CIs calculated using the Cox proportional hazard regression model, P values calculated using the log-rank test, and the NNT are shown where appropriate. (A) Treated vs control, CaHUS with mutation or FHAA. (B) Children vs adults, CaHUS with mutation or FHAA. (C) Control group based on the mutation type. (D) Treated group, based on the mutation type. (E) Treated vs control, individuals with CFH mutation subgroup. (F) Treated vs control, individuals with CD46 mutation subgroup.